Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
GLENMARK PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GLENMARK PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
GLENMARK PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 487 | 3,486 | - | |
Low | Rs | 349 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 460.4 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 13.4 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 35.0 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 2.50 | 109.40 | - | |
Avg Dividend yield | % | 0.6 | 3.4 | 17.8% | |
Book value per share (Unadj.) | Rs | 335.1 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 282.17 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.9 | 1.6 | 55.8% | |
Avg P/E ratio | x | 31.3 | 26.1 | 119.9% | |
P/CF ratio (eoy) | x | 11.9 | 11.4 | 105.0% | |
Price / Book Value ratio | x | 1.2 | 1.5 | 85.1% | |
Dividend payout | % | 18.7 | 87.5 | 21.4% | |
Avg Mkt Cap | Rs m | 117,953 | 2,761,843 | 4.3% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 27,810 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 129,901 | 1,696,422 | 7.7% | |
Other income | Rs m | 3,168 | 0 | - | |
Total revenues | Rs m | 133,069 | 1,696,422 | 7.8% | |
Gross profit | Rs m | 15,125 | 464,566 | 3.3% | |
Depreciation | Rs m | 6,113 | 137,123 | 4.5% | |
Interest | Rs m | 3,496 | 33,320 | 10.5% | |
Profit before tax | Rs m | 8,685 | 294,122 | 3.0% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 4,911 | -3,591 | -136.7% | |
Profit after tax | Rs m | 3,774 | 105,974 | 3.6% | |
Gross profit margin | % | 11.6 | 27.4 | 42.5% | |
Effective tax rate | % | 56.5 | -1.2 | -4,631.3% | |
Net profit margin | % | 2.9 | 6.2 | 46.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 98,737 | 1,145,757 | 8.6% | |
Current liabilities | Rs m | 50,455 | 999,197 | 5.0% | |
Net working cap to sales | % | 37.2 | 8.6 | 430.2% | |
Current ratio | x | 2.0 | 1.1 | 170.7% | |
Inventory Days | Days | 7 | 91 | 7.4% | |
Debtors Days | Days | 115 | 96 | 120.1% | |
Net fixed assets | Rs m | 76,920 | 554,089 | 13.9% | |
Share capital | Rs m | 282 | 4,176 | 6.8% | |
Net worth | Rs m | 94,563 | 1,884,403 | 5.0% | |
Long term debt | Rs m | 38,521 | 867,418 | 4.4% | |
Total assets | Rs m | 175,658 | 3,876,868 | 4.5% | |
Interest coverage | x | 3.5 | 9.8 | 35.5% | |
Debt to equity ratio | x | 0.4 | 0.5 | 88.5% | |
Sales to assets ratio | x | 0.7 | 0.4 | 169.0% | |
Return on assets | % | 4.1 | 3.6 | 115.2% | |
Return on equity | % | 4.0 | 5.6 | 71.0% | |
Return on capital | % | 9.2 | 4.9 | 185.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,254 | 270,322 | 2.3% | |
From Investments | Rs m | -5,285 | -95,786 | 5.5% | |
From Financial Activity | Rs m | -775 | -324,269 | 0.2% | |
Net Cashflow | Rs m | 325 | -149,733 | -0.2% |
Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare GLENMARK PHARMA With: EVEREST ORGANICS BDH INDUS. VENUS REMEDIES COLINZ LABOR J.B.CHEMICALS
It was indeed a volatile trading session for Indian share markets yesterday.